ANI Pharmaceuticals Offers SEK 11.25 Per Egetis Share

ANI's third and final bid for Swedish drugmaker Egetis Therapeutics has been unanimously recommended by Egetis' board.

Updated on Nov. 19, 2026 in Corporate Finance

Wide view of a low modern pharmaceutical facility with pale concrete and glass walls under overcast daylight, with a tall steel stack at the edge of the frame.
ANI Pharmaceuticals offered SEK 11.25 per share for Swedish drugmaker Egetis Therapeutics, a third and final bid that Egetis's board unanimously recommended. AI Illustration. Upload story photo >

ANI Pharmaceuticals, Inc. announced a recommended public cash offer for Egetis Therapeutics AB shares, the Convertible, and the Warrants, at SEK 11.25 per share. The Egetis Board unanimously recommended the offer, which followed a competitive bidding process conducted with its financial advisor.

Why it matters

The offer follows a competitive bidding process, and the Egetis Board's unanimous endorsement signals that the final price was judged acceptable to the company's leadership. With shareholders representing about 42.2 percent of outstanding shares committed to accept, the offer has substantial early support for a transaction that would transfer control of the Swedish company to a U.S. buyer.

The offer terms set cash prices of SEK 11.25 per share, SEK 65,750,817 for the Convertible and SEK 6.99 per Warrant, with about 42.2 percent of outstanding shares committed to accept. Whether the offer becomes unconditional, and whether ANI raises its price, remains unresolved, as ANI has said it will not increase the price unless a competing offer is announced.

The players

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals is a U.S.-based specialty pharmaceutical company that develops and markets generic and branded prescription medicines.

Egetis Therapeutics AB (publ)

Egetis Therapeutics is a Swedish biopharmaceutical company focused on developing treatments for rare pediatric metabolic diseases.

The details

The acceptance period runs from November 20, 2026, to 17.00 CET on December 18, 2026. Shareholders holding shares in nominee accounts must follow their nominee's instructions, while directly registered shareholders must submit a signed acceptance form to Handelsbanken's issue department.

Timeline

  1. November 5, 2026: ANI announces the recommended public cash offer.

  2. November 19, 2026: The Swedish Financial Supervisory Authority approves and registers the offer document.

  3. November 20, 2026: The acceptance period begins.

  4. December 18, 2026: The acceptance period expires at 17.00 CET.

  5. December 29, 2026: Settlement is expected to begin, if the offer is declared unconditional by around December 21.

Market Dynamics

The offer reflects a bidding contest for a Swedish listed drugmaker, in which a recommended final cash price follows multiple competing approaches. Its acceptance period and regulatory approval place it within the standard framework of public cash offers supervised by the Swedish Financial Supervisory Authority.

Egetis shareholders who accept must follow their nominee's instructions or submit a signed form to Handelsbanken by the December 18, 2026 deadline, or they may miss the SEK 11.25 cash price. Holders of the Convertible and Warrants receive fixed cash amounts of SEK 65,750,817 and SEK 6.99 per Warrant if they accept.

The takeaway

Shareholders holding about 42.2 percent of Egetis already support the deal, so the acceptance outcome will depend on whether the remaining holders act before the December 18 deadline. Investors who want the cash price should confirm their acceptance route with their nominee or bank well ahead of that date.

What happens next

The acceptance period expires on December 18, 2026, and settlement is expected around December 29, 2026, if the offer is declared unconditional by around December 21.

Further reading

For more on how deals like this are structured, explore Corporate Finance coverage on Wisevoter.

More information

Review the full terms on the Offer document and transaction website.

Source note: This article includes information reported by Firstwordpharma.